The authors regret to inform that we recently discovered an error in this article. One of the exosomal miRNAs that was detected in all patient samples, miR-29a-3p, was in the article erroneously labeled and described as being significantly differently expressed between two patient groups (TRG 1 versus TRG 2-3) within the investigation and validation cohorts. Fortunately, miR-29a-3p had not been selected for down-stream analyses, averting consequential errors within the study.
Below follows a list of edits pertaining to the correct labeling of miR-29a-3p as not being differently expressed between the patient groups TRG 1 and TRG 2-3 in the investigation and validation cohorts. The edits are in bold and underlined.
We sincerely regret if our inadvertent mistake has caused confusions. The conclusions drawn from the experiments are not affected.
1. Results, the first and second paragraphs, should read: Of the initial 372 exosomal miRNAs tested in the investigation cohort, 44 were detected in all samples, with an average of 135 miRNAs per sample ( Supplementary Table 2 and Supplementary  Table 3A ). Analysis with SAM uncovered 37 miRNAs with significantly altered expression according to N-or M-status, or TRG ( Supplementary Table 1 ). Of these, five miRNAs with a strong probability of relation to M-status and TRG were verified using single parameter Student's t test ( Supplementary Table 1 ).
The observed significant associations presented in Figure 1 show that there was no difference in expression of miR-29a-3p between TRG groups, and low levels of miR-301a-3p were found in patients with poor tumor response (TRG 2-3) to neoadjuvant therapy in the investigation cohort. Further, miR-141-3p, miR-375, miR-423-5p, and miR-431-3p were all found to be higher expressed in patients with synchronous liver metastasis. The top six miRNAs were selected for validation along with seven miRNAs as reference for normalization.
2. The corrected Figure 1 is shown below, where the erroneous asterisks in panel E have been removed. This does not affect the figure legend, which reads as in the published article version. 3. Supplementary Table 1 miRNA selection overview. In the investigation cohort, 36 miRNAs had significantly altered expression according to node (N) or metastatic (M)-status, or tumor regression grade (TRG) noted as fold change between the groups in the Significance Analysis of Microarrays (SAM) software. Of these 36, five were verified using single parameter Student's t test. We selected the top six for validation, and added another 7 miRNAs with the highest stability to validate in the independent validation cohort.
The authors would like to apologise for any inconvenience caused. 
